1.Optimizing oral antithrombotic therapy in patients post percutaneous coronary intervention
Chinese Journal of Interventional Cardiology 2025;33(11):601-613
Oral anti-thrombotic medication management is crucial for patients post percutaneous coronary intervention(PCI).Identifying the optimal balance between ischemic and hemorrhagic risks has consistently been a highly concerning and urgent issue for clinicians.Given individual variations in risk and drug responses,guideline-recommended strategies may not suit all patients.Recent studies have explored tailored anti-thrombotic strategies for diverse groups,providing evidence for guideline revisions and offering multiple clinical treatment options.However,patient assessment,adjustment timing,and strategy formulation lack standardization and flexibility,necessitating professional consensus.This consensus statement,carefully crafted to meet clinical needs,emphasizes dynamic assessment and holistic management,prioritizing individual differences and patient adherence.It aims to offer practical,optimized anti-thrombotic regimens to improve patients' long-term outcomes.
2.Quality control report of Heart Valve Center in 2024
Da-xin ZHOU ; Yong-jian WU ; Jian-an WANG ; Jun-bo GE
Chinese Journal of Interventional Cardiology 2025;33(11):614-619
With the aging of the population,the disease burden of heart valve disease in China has significantly increased.In recent years,the interventional treatment for heart valve disease has flourished,among which transcatheter aortic valve replacement(TAVR)has become the first-line treatment for elderly patients with aortic valve stenosis.China started relatively late in the field of interventional treatment for heart valve disease.The construction of heart valve centers helps to standardize the diagnosis and interventional treatment of heart valve disease in China and improve the management of prognosis for patients.Up to December 2024,a total of 453 centers have participated in the construction of heart valve centers,including 100 construction centers and 40 certification centers.The National Transcatheter Valve Therapeutics Registry(NTCVR)database has reported a total of 28 594 cases,with approximately 50%of Chinese TAVR cases recorded in NTCVR database.The construction of the heart valve centers has shown initial results,significantly optimizing the process of diagnosis and treatment of heart valve disease and improving the prognosis.At present,there are still many shortcomings in the construction of heart valve centers.For example,the follow-up rate of patients after discharge is low,and long-term management after discharge needs to be further improved.There is still a gap in some indicators between construction centers and certification centers,and the promotion of high-quality management of interventional treatment of heart valve disease in China is still a long way to go.
3.To explore the safety and efficacy of applying Bivalirudin during perioperative period of percutaneous coronary intervention in complex high-risk and indicated patients with extracorporeal membrane oxygenation
Ling YANG ; Cheng-cheng YI ; Yu PENG ; Zheng ZHANG
Chinese Journal of Interventional Cardiology 2025;33(11):620-626
Objective To explore the safety and efficacy of applying Bivalirudin in complex high-risk and indicated patients(CHIP)undergoing percutaneous coronary intervention(PCI)while on extracorporeal membrane oxygenation(ECMO).This study will provide additional evidence for making informed decisions regarding anticoagulation therapy during ECMO.Methods A total of 83 CHIP who underwent VA-ECMO assisted PCI in the Heart Center of the First Hospital of Lanzhou University from March 2019 to December 2022 were retrospectively enrolled as the research objects.According to the use of anticoagulant drugs during ECMO support and PCI,they were divided into Bivalirudin group(40 cases)and heparin group(43 cases).The cost of anticoagulants,coefficient of variation of activated partial thromboplastin time(APTT),APTT compliance rate,bleeding events,thrombotic events,blood product transfusion,and net adverse clinical events(NACE)at 30 days after PCI were compared between the two groups to determine the safety and efficacy of Bivalirudin in CHIP undergoing ECMO assisted PCI.Results The proportion of previous PCI(25.00%vs.4.65%),fibrinogen level[(3.52±1.14)g/L vs.(2.92±1.28)g/L],CRUSADE score[(32.00±12.69)scores vs.(26.14±10.60)scores],anticoagulation cost[1 400.00(700.00,2 100.00)RMB vs.107.69(58.74,205.59)RMB]and compliance rate of APTT[(57.76±33.11)%vs.(31.44±27.63)%]in the Bivalirudin group were higher,while the coefficient of variation for APTT[10.64(7.72,21.11)vs.19.47(10.48,31.28)]was lower than those in the heparin group.The total bleeding events(25.00%vs.46.51%),Bleeding Academic Research Consortium(BARC)1-2 bleeding events(12.50%vs.32.56%),and total thrombotic events(12.50%vs.32.56%)of the Bivalirudin group was significantly lower compared with the heparin group.Kaplan-Meier curves showed that cumulative incidence of 30-days NACE was significantly lower in the Bivalirudin group than in the heparin group.The differences between the above two groups were statistically significant(Log-rank P<0.001).Conclusions Compared with heparin,Bivalirudin has better safety and efficacy in CHIP undergoing PCI assisted by VA-ECMO.
4.Clinical study on the effect of aortic remodeling after bare stent implantation for aortic dissection
Wei QIN ; Kan YANG ; Dong HAN ; Di-kun FAN ; Jie CUI
Chinese Journal of Interventional Cardiology 2025;33(11):627-633
Objective To compare the differences in clinical prognosis and safety between thoracic endovascular aortic repair(TEVAR)combined with bare metal stent(BMS)implantation therapy and TEVAR alone in patients with type B aortic dissection(TBAD)after 6 months.Methods The clinical and imaging data of patients diagnosed with TBAD and treated with TEVAR or TEVAR combined with BMS implantation in Nanyang Central Hospital from March 2023 to March 2024 were retrospectively collected.The patients were divided into TEVAR group and TEVAR+BMS group according to different treatment methods.The aortic remodeling indicators and postoperative complications at discharge and 6 months after surgery were compared between the two groups.Results A total of 37 patients were included,including 20 patients in the TEVAR group and 17 patients in the TEVAR+BMS group.There were no statistically significant differences in baseline data between the two groups(all P>0.05);at discharge and 6 months after surgery,the true lumen diameters and true lumen ratios of the abdominal aorta(proximal level of the celiac trunk and proximal level of the left renal artery)in the TEVAR+BMS group were better than those in the TEVAR group(all P<0.05);the degree of thrombosis of the false lumen at 6 months after surgery was better in the TEVAR+BMS group than in the TEVAR group(P<0.05);there was no statistically significant difference in postoperative complications between the two groups(P>0.05).Conclusions TEVAR combined with BMS implantation therapy can significantly improve the aortic remodeling effect of patients with TBAD,without increasing the risk of postoperative complications and death caused by aortic-related factors.Bare stent implantation as an auxiliary treatment method for endovascular repair is a safe and effective optimized treatment plan.
5.Analysis of the safety of intravascular lithotripsy and rotational atherectomy in the management of coronary artery calcification
Zhang-ying WU ; Li ZHU ; Su LI ; Jia HUANG ; Yu-xiang DAI
Chinese Journal of Interventional Cardiology 2025;33(11):634-639
Objective To investigate the safety of intravascular lithotripsy(IVL)and coronary rotational atherectomy(RA)in the management of coronary artery calcification(CAC).Methods In this retrospective,matched-pair cohort study,210 patients with severe CAC treated at Zhongshan Hospital,Fudan University between December 2021 and April 2025 were enrolled.The cohort was equally divided into two interventional groups:IVL group(n=105)and RA group(n=105),based on the revascularization strategy employed.Procedure parameters,postoperative biochemical markers of myocardial injury,and incidence of in-hospital major adverse cardiovascular events(MACE)were compared between the two groups.Results Before propensity score matching(PSM),statistically significant differences were observed in terms of the proportions of the left anterior descending artery(77.1%vs.63.8%,P=0.034),the right coronary artery(14.3%vs.30.5%,P=0.005),and the percentage of target vessel stenosis[85%(80%,90%)vs.80%(80%,90%),P=0.014]between the IVL and RA groups.After PSM,these differences became insignificant(all P>0.05).There is no statistically significant differences in stent implantation rate,drug-coated balloon usage rate,stent diameter,or total stent length between the IVL and RA groups(all P>0.05).Compared to the RA group,although the IVL group had a higher utilization of tirofiban after the procedure,and a lower rate of intravenous nitrate during the procedure,these differences were not statistically significant(all P>0.05).cTnT levels increased significantly after the procedure in both the IVL and RA groups(all P<0.001).Before PSM,the preoperative cTnT levels were comparable between the IVL and RA groups(P=0.525),while a statistically significant difference emerged postoperatively(P=0.038).The incidence of in-hospital myocardial infarction showed no significant intergroup difference(8.6%vs.16.2%,P=0.094),and no events of death or target vessel revascularization occurred in either group.After PSM,despite no significant difference in preoperative cTnT levels between the IVL and RA groups(P=0.235),a significant difference was observed postoperatively(P=0.014).Furthermore,while no deaths or target vessel revascularization occurred in either group,the IVL group demonstrated a significantly lower incidence of in-hospital myocardial infarction compared to the RA group(9.9%vs.23.9%,P=0.025).Conclusions The use of intravascular lithotripsy for the pretreatment in patients with severe CAC is safe and promising.
6.Comparison of clinical outcomes of drug-coated balloon treatment for in-stent restenosis with different clinical presentations
Hui-fang ZHANG ; Hong-yong SONG ; Guo LI ; Dong-fang HE ; Qian TAO
Chinese Journal of Interventional Cardiology 2025;33(11):640-646
Objective To compare the clinical outcomes of patients with coronary in-stent restenosis(ISR)who underwent drug-coated balloon(DCB)treatment,based on different clinical presentations.Methods This prospective study included 508 patients diagnosed with coronary ISR at Anzhen Hospital,Capital Medical University,between May 2020 and May 2022.All patients received DCB treatment.According to clinical presentation,the patients were divided into an acute coronary syndrome(ACS)group(185 patients)and a non-acute coronary syndrome(non-ACS)group(323 patients).All patients were followed for two years,primarily comparing the incidence of myocardial infarction(MI),target lesion revascularization(TLR),death,and major adverse cardiovascular events(MACE)between the two groups.Results Baseline data showed that the ACS group had a significantly higher proportion of hypertension,diabetes,and smoking compared to the non-ACS group(all P<0.05).Additionally,the ACS group had a higher proportion of B2/C-type lesions,long lesions,and moderate to severe calcified lesions(all P<0.05).The number,length,and diameter of stents implanted were also significantly larger in the ACS group(all P>0.05).At the 1-year follow-up,the ACS group had a significantly higher incidence of TLR(8.1%vs.2.5%,P=0.007)and MACE(10.3%vs.5.3%,P=0.047)than the non-ACS group.By the end of the 2-year follow-up,the ACS group still had higher rates of TLR(18.9%vs.10.2%,P=0.007)and MACE(22.7%vs.14.9%,P=0.030).Conclusions ISR patients with ACS have higher cardiovascular risk and more complex lesions.They also experience a higher incidence of adverse events after DCB treatment.
7.Research progress in drug formulation of paclitaxel coated balloon catheter
Chinese Journal of Interventional Cardiology 2025;33(11):647-651
Paclitaxel drug coated balloon catheter is an important and effective treatment in the field of luminal stenosis,which can deliver the drug precisely to the lesion,inhibiting the proliferation of smooth muscle cells,and reducing the rate of restenosis.Optimizing the drug formulation,reducing the loss of paclitaxel during delivery,improving the transfer rate of paclitaxel in the lesion site,and prolonging the drug's retention time in the tissue,are the core of the development of paclitaxel drug coated balloon catheter.To drug formulation,different dosage forms of paclitaxel,such as amorphous,crystalline,liposome,nanoparticles,etc.,can directly affect the transfer rate of paclitaxel on balloon surface and its metabolic rate in tissue.The use of different ratios and kinds of excipients,such as hydrophilic,lipophilic and amphiphilic,can have different effects on drug adhesion,release speed and retention time in tissues.In addition,the way of paclitaxel loaded on the balloon can also affect the clinical efficacy of the drug coated balloon.
8.Re-understanding of pulsed electric field ablation for atrial fibrillation
Jian-gang XU ; Kang LI ; Jin-lin ZHANG ; Zu-lu WANG
Chinese Journal of Interventional Cardiology 2025;33(11):652-656
Catheter-based pulsed field ablation(PFA)for atrial fibrillation ablation has been widely adopted worldwide in recent years,accumulating substantial evidence for its efficacy and safety.However,several adverse events associated with this technology have also been observed,such as PFA-related coronary artery spasm,hemolysis,acute renal injury,and symptomatic or asymptomatic cerebrovascular events.This review summarizes the latest basic and clinical research advances in PFA over the past two years,focusing on biophysical aspects including the field intensity of PFA,the thermal effects of PFA,contact force,and the number of applications.We discuss whether PFA demonstrates tissue selectivity,the mechanisms of hemolysis and microbubble formation,as well as the lesion morphology and impact factors to lesion depth.This review aims to provide clinicians with a more in-depth understanding of PFA technology and biphasic to optimize clinical application.
9.Using of Lawnest,an intravascular snare in retrograde percutaneous coronary intervention for chronic total occlusion:a case report
Ying-kai LI ; Song-yuan HE ; Zi-chao CHENG ; Hong-yu PENG
Chinese Journal of Interventional Cardiology 2025;33(11):657-660
Coronary chronic total occlusion(CTO)remains a significant challenge in the field of interventional therapy for coronary artery disease.With advancements in interventional techniques,particularly retrograde approaches,the success rate of CTO interventions has improved.The key steps of retrograde intervention include traversing collateral channels with the retrograde guidewire,wiring the occlusion segment,and establishing antegrade access.In this case,the patient had a heavily calcified occlusion at the left circumflex artery(LCX)ostium jailed by the prior stent implanted in the left main and anterior descending arteries,making it difficult to establish antegrade access using conventional methods after retrograde guidewire crossing.The procedure was successfully completed by employing a domestically developed intravascular snare system combined with a pre-assembled extension catheter technique to capture the retrograde guidewire and establish antegrade access,followed by stent implantation at the LCX ostium.This innovative approach provides a new strategy for complex CTO retrograde interventions,particularly in cases where retrograde guidewire entry into the antegrade guiding catheter is challenging.
10.2024 annual report of interventional treatment for heart failure
Chang-dong ZHANG ; Yu-cheng ZHONG ; Geng LI ; Jie WU ; Jun TIAN ; Zhi-cheng JING ; Wei MA ; Nian-guo DONG ; Yong-jian WU ; Da-xin ZHOU ; Xiao-ke SHANG
Chinese Journal of Interventional Cardiology 2025;33(10):581-587
China has become the country with the highest global burden of heart failure(HF).Despite the widespread use of prognostic-improving medications today,the mortality rate of HF remains high,reaching 13.7%at one year-particularly among patients with heart failure with reduced ejection fraction(HFrEF).HF interventional device therapy(structural intervention)targets the structural factors underlying HF,including atrial pressure,ventricular remodeling,and valvular intervention.It leverages the heart's intrinsic physiological properties and pathological progression mechanisms to deliver treatments through interventions without external active forces,achieving anatomical or functional repair.This field has emerged as a rapidly growing area and plays an increasingly critical role in HF management.This article provides a comprehensive review and summary of the latest advancements in HF and cardiomyopathy interventional therapy over the past year.It covers various novel technologies and products currently in the research phase,aiming to provide an in-depth analysis of the current status and future directions of HF interventional therapy,and further advance the development of this discipline.

Result Analysis
Print
Save
E-mail